The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap: Avadel Pharmaceuticals Q4 Earnings
Avadel Pharmaceuticals (NASDAQ:AVDL) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Avadel Pharmaceuticals Q4 EPS $(0.38) Beats $(0.41) Estimate
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 100 percent decrease over losses of $(0.19) per share
Needham Maintains Buy on Avadel Pharmaceuticals, Lowers Price Target to $15
Needham analyst Ami Fadia maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and lowers the price target from $16 to $15.
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Avadel Pharma Highlights New Data On Once-At-Bedtime FT218, Preference For Once-Nightly Dosing In Patients With Narcolepsy At American College of Chest Physicians Meeting
- Post-hoc responder analyses demonstrated a significantly greater proportion of patients receiving FT218 experienced reductions in weekly cataplexy attacks and improvement in mean sleep latency compared to placebo -
-